We are live on ! Find out more
NVS icon

Novartis

830 hedge funds and large institutions have $20.6B invested in Novartis in 2014 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 309 increasing their positions, 318 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 41

15% more funds holding in top 10

Funds holding in top 10: 5260 (+8)

2% more funds holding

Funds holding: 815830 (+15)

4% more capital invested

Capital invested by funds: $19.8B → $20.6B (+$742M)

0.17% less ownership

Funds ownership: 9.99%9.82% (-0.17%)

3% less repeat investments, than reductions

Existing positions increased: 309 | Existing positions reduced: 318

5% less call options, than puts

Call options by funds: $182M | Put options by funds: $192M

Holders
830
Holders Change
+15
Holders Change %
+1.84%
% of All Funds
23.97%
Holding in Top 10
60
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+15.38%
% of All Funds
1.73%
New
61
Increased
309
Reduced
318
Closed
41
Calls
$182M
Puts
$192M
Net Calls
-$10M
Net Calls Change
-$58M
Name Holding Trade Value Shares
Change
Change in
Stake
GC
201
Grimes & Company
Massachusetts
$7.26M +$251K +3,441 +4%
AC
202
AFAM Capital
Texas
$7.24M +$47K +645 +0.7%
SSB
203
Sandy Spring Bank
Maryland
$7.2M +$56.2K +771 +0.8%
VW
204
Vantage Wealth
California
$7.14M +$16.3K +224 +0.2%
Jane Street
205
Jane Street
New York
$7.07M +$2.35M +32,234 +53%
CIM
206
Corda Investment Management
Texas
$7.03M -$68K -933 -1%
GJIC
207
Gamble Jones Investment Counsel
California
$7.03M -$187K -2,567 -3%
LI
208
LMCG Investments
Massachusetts
$6.96M +$16.3K +223 +0.2%
JGUA
209
John G. Ullman & Associates
New York
$6.95M -$330K -4,531 -5%
PA
210
Pinnacle Associates
New York
$6.93M +$129K +1,769 +2%
PAM
211
Private Asset Management
California
$6.87M +$40.2K +552 +0.6%
MA
212
MUFG Americas
New York
$6.78M +$319K +4,382 +5%
AIP
213
ARS Investment Partners
New York
$6.75M -$334K -4,584 -5%
WIC
214
Wilkins Investment Counsel
Massachusetts
$6.66M -$32.5K -446 -0.5%
CCT
215
Country Club Trust
Missouri
$6.6M +$180K +2,477 +3%
RIM
216
RS Investment Management
California
$6.51M -$285K -3,912 -4%
HNB
217
Huntington National Bank
Ohio
$6.48M -$125K -1,716 -2%
CRC
218
Curi RMB Capital
Illinois
$6.38M -$970K -13,313 -14%
Jones Financial Companies
219
Jones Financial Companies
Missouri
$6.34M +$287K +3,934 +5%
BCB
220
Brian C. Broderick
$6.22M +$802 +11 +0%
OWD
221
Osborn Williams & Donohoe
Ohio
$6.2M -$17.9K -245 -0.3%
B
222
Baird
Wisconsin
$6.07M -$33.6M -461,689 -85%
MSA
223
Mason Street Advisors
Wisconsin
$6.06M
BFG
224
Beacon Financial Group
Texas
$6.04M -$373K -5,124 -6%
CTA
225
Chesley Taft & Associates
Illinois
$5.97M +$74.2K +1,018 +1%

NVS Hedge Fund Activity: Q1 2014 in Review

830 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2014, worth a combined $20.6B — up 3.7% from $19.8B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new NVS positions and 41 closed out — a net gain of 20 holders — while 309 added to existing stakes and 318 trimmed.

The largest buyer was Loomis, Sayles & Company, adding an estimated $68.5M. The largest seller was Primecap Management, cutting an estimated $220M.

  • 830 institutional investors held Novartis (NVS) as of Q1 2014, up from 815 in Q4 2013.
  • Funds reported $20.6B of Novartis stock for Q1 2014, up 3.7% quarter-over-quarter.
  • 61 funds opened new Novartis positions in Q1 2014 and 41 closed out, a net change of +20 holders.
  • The largest Novartis buyer in Q1 2014 was Loomis, Sayles & Company, an estimated $68.5M added.
  • The largest Novartis seller in Q1 2014 was Primecap Management, an estimated $220M sold.

Based on aggregated 13F filings for Q1 2014.